Manufacturers exploring opportunities in global markets face dynamic demographic and disease trends, changing market demands, and evolving regulatory requirements—all of which differ from one country to another. While emerging markets continue to represent a new channel of demand for pharmaceutical products, manufacturers have quickly realized that significant attention must still…
Expanding government and payer requirements for additional data on products, whether for safety monitoring, efficacy confirmation or economic and clinical value evaluation, underscore the importance of an integrated strategy for investigator initiated trials (IIT) and real world evidence (RWE) research. In developing an IIT/RWE strategy, companies need to be clear…
As life sciences companies address Sunshine Act requirements and other growing demands for transparency, they also face concerns from physicians that this publically available information may distort the often necessary and beneficial aspects of relationships physicians maintain with industry. Already, anecdotal evidence indicates some physicians will be reluctant to work…
Professional relationships with physicians are extremely important sources of collaboration for medical products companies. Physicians provide technical input, identify unmet needs, and perhaps most critically, conduct clinical trial administration and oversight. But these very areas have been underlined by OIG and DOJ investigators as targets of special scrutiny going forward.…
The global market for pharmaceuticals continues to grow as manufacturers move to expand their market strategy and product pipeline to new markets and therapeutic areas. Increasing globalization has fueled changes in the regulatory environment, including increased data requirements at the various stages of product development, validation, approval, and production. Additionally,…
Finding the right CCO isn’t a simple hiring decision for life sciences companies. They face a range of complex business, regulatory, and market challenges in a dynamic and heavily scrutinized environment. Creating and maintaining a culture of ethics and compliance isn’t about just about the CCO. It’s a decision that…
